China’s securities regulator is raising the bar for humanoid robot companies seeking to list publicly, tightening scrutiny over revenue, losses, and technology as regulators and investors become more concerned that the country’s booming “embodied AI” sector may be running ahead of its commercial prospects.
The China Securities Regulatory Commission, or CSRC, is privately advising humanoid robot startups to meet as many as three requirements before pursuing an initial public offering, according to three people familiar with the regulator’s thinking cited by CNBC.
The companies are expected to demonstrate sustainable revenue and commercial orders, show a path toward narrowing losses, and possess core technologies such as a robotic “brain” or advanced robotic hands, the sources said.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
One source said a company may ultimately need to satisfy only two of the three conditions, but it remains unclear which criteria could be sufficient.
A source told Reuters earlier this month that humanoid IPOs had effectively been frozen for now, while another described the move as a sector-specific slowdown rather than a formal ban.
The guidance could sharply reduce the number of humanoid robotics companies capable of reaching public markets. At least two dozen companies involved in embodied AI have filed to list in Hong Kong, according to two of the sources, but the new requirements have lowered expectations that many of them will make it through the regulatory process.
The regulatory shift comes as China’s humanoid robotics industry experiences a striking contrast between capital inflows and commercial performance. Investment has surged, valuations have risen, and Beijing has promoted embodied AI as an important emerging technology, while several companies continue to generate losses and face questions about whether humanoid robots can deliver commercially useful applications at scale.
Unitree Becomes A Test Of The Sector’s Valuation
The market’s reassessment has been particularly visible in Unitree, one of China’s best-known humanoid robotics companies.
Unitree received regulatory fast-track treatment for its Shanghai listing on August 19, coinciding with the opening of the World Robot Conference in Beijing. The company raised about 6.1 billion yuan ($905 million), and its Shanghai-listed shares surged more than 460% on their first trading day, closing at 845 yuan.
The enthusiasm did not last.
By Monday, the stock had fallen to 459.65 yuan, almost half its debut price.
The reversal has added weight to concerns over whether public-market valuations are getting ahead of the technology’s ability to generate revenue.
Those concerns were reinforced when Unitree founder Wang Xingxing said at the World Robot Conference that meaningful commercialization beyond applications such as dancing robots remained years away. Wang’s comment helped intensify a broader debate over what today’s humanoid robots can actually do in commercial environments and, more importantly, whether the companies developing them are generating enough revenue to justify their valuations.
China now has well over 100 humanoid robotics companies operating within the broader embodied AI sector. The government’s endorsement of embodied AI in its last two annual work reports has helped attract substantial investment, but Chinese authorities have also warned about the possibility of a bubble in the industry.
The numbers illustrate the speed of the capital inflow. Investment in the sector reached 47.09 billion yuan ($6.95 billion) in the second quarter, more than twice the first-quarter amount and more than six times the level recorded during the same period a year earlier, according to industry data provider Xiniu.
The regulatory response suggests Beijing wants the next stage of the industry to be determined less by fundraising and headline valuations and more by evidence that companies can commercialize the technology.
Revenue and Technology Become The Dividing Line
The CSRC’s reported criteria are significant because they target three weaknesses that are common among early-stage robotics companies: limited commercial revenue, persistent losses, and dependence on externally developed technology.
Requiring sustainable revenue and actual commercial orders would distinguish companies selling functioning robotic systems from startups whose valuations are largely based on future expectations.
A requirement for losses to narrow would impose another hurdle on businesses still spending heavily on research, manufacturing capacity and product development. One source said companies could be required to provide a three-year forecast showing how their financial performance will improve.
The technology requirement could be equally important.
Humanoid robotics combines artificial intelligence, sensors, actuators, batteries, semiconductor technology and mechanical engineering. A company that assembles existing components without possessing proprietary technology could find it harder to justify a public-market valuation based on long-term technological leadership.
The regulator’s focus on robotic brains or hands therefore points toward a distinction between companies building core intellectual property and those primarily integrating technologies developed elsewhere.
That could leave a much smaller group of potential IPO candidates.
The pressure is already visible among listed companies. Hong Kong-listed Ubtech, which went public in December 2023, has fallen more than 40% this year. The company reported an operating loss of 279 million yuan in the first half of the year.
Its performance highlights the difficulty of translating technological progress into financial results. Even companies that have already accessed public markets remain under pressure to demonstrate that the enormous investment flowing into robotics can eventually produce sustainable earnings.
China’s Physical AI Boom Faces a Broader AI Valuation Test
The scrutiny of humanoid robotics is also part of a wider reassessment of AI valuations.
Investors have poured money into technologies ranging from large language models to robotics and AI infrastructure on the assumption that artificial intelligence will create enormous new markets. Humanoid robots have attracted particular attention because they could eventually bring AI into physical environments such as factories, warehouses, logistics operations and homes.
For early-stage investors, that makes robotics an extension of the AI investment story.
But the economics are much less mature than the narrative.
Rhodium Group analysis this month found that Chinese AI companies generate only about 10% of the revenue of OpenAI and Anthropic combined. It also found that the ratio of valuation to revenue for some Chinese AI startups, including Moonshot and DeepSeek, was substantially higher than for their U.S. counterparts.
The comparison is relevant to robotics because many of the same investment dynamics are present. Investors are assigning substantial valuations to companies based on expected future technological breakthroughs and market adoption, while current revenue remains relatively limited.
The CSRC’s reported guidance could therefore mark an attempt to impose a clearer contrast between technological potential and demonstrated commercial performance.
That does not mean Beijing is abandoning humanoid robotics. The government’s support for embodied AI remains intact, and investment continues to rise. Instead, the regulatory message appears to be that access to public markets will require stronger evidence that individual companies can convert that investment into commercially viable businesses.
The gap is becoming increasingly wide as investors move from funding the technology’s development to demanding evidence of returns. The market’s treatment of Unitree offers an early indication of how quickly sentiment can change. Its shares initially soared more than fourfold, only to lose almost half their value within weeks.
For China’s humanoid robotics industry, the next phase may be more about which ones can demonstrate recurring revenue, shrinking losses and genuine technological differentiation. That is also likely to determine how many of the more than two dozen companies seeking Hong Kong listings ultimately make it to the public market.